Literature DB >> 10770913

1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus.

.   

Abstract

Entities:  

Mesh：

Year:  2000        PMID： 10770913     DOI： 10.1086/313848

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  11 in total

1.  Hepatitis B or hepatitis C virus infection is a risk factor for severe hepatic cytolysis after initiation of a protease inhibitor-containing antiretroviral regimen in human immunodeficiency virus-infected patients. The APROCO Study Group.

Authors:  M Savès; F Raffi; P Clevenbergh; B Marchou; A Waldner-Combernoux; P Morlat; V Le Moing; C Rivière; G Chêne; C Leport
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

Review 2.  Pneumococcal vaccination among HIV-infected adult patients in the era of combination antiretroviral therapy.

Authors:  Kuan-Yeh Lee; Mao-Song Tsai; Kuang-Che Kuo; Jen-Chih Tsai; Hsin-Yun Sun; Aristine C Cheng; Sui-Yuan Chang; Chen-Hsiang Lee; Chien-Ching Hung
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

3.  Estimates of opportunistic infection incidence or death within specific CD4 strata in HIV-infected patients in Abidjan, Côte d'Ivoire: impact of alternative methods of CD4 count modelling.

Authors:  Sylvie Deuffic-Burban; Elena Losina; Bingxia Wang; Delphine Gabillard; Eugène Messou; Nomita Divi; Kenneth A Freedberg; Xavier Anglaret; Yazdan Yazdanpanah
Journal:  Eur J Epidemiol       Date:  2007-09-08       Impact factor: 8.082

4.  Interaction between saquinavir soft-gel and rifabutin in patients infected with HIV.

Authors:  G J Moyle; N E Buss; T Goggin; P Snell; C Higgs; D A Hawkins
Journal:  Br J Clin Pharmacol       Date:  2002-08       Impact factor: 4.335

5.  Late diagnosis of HIV infection at two academic medical centers: 1994-2004.

Authors:  M Jean-Jacques; R P Walensky; W H Aaronson; Y Chang; K A Freedberg
Journal:  AIDS Care       Date:  2008-09

Review 6.  Mucosal and systemic fungal infections in patients with AIDS: prophylaxis and treatment.

Authors:  Markus Ruhnke
Journal:  Drugs       Date:  2004       Impact factor: 9.546

7.  Preparation of the HIV-infected Traveler to the Tropics.

Authors:  Christopher L. Karp
Journal:  Curr Infect Dis Rep       Date:  2001-02       Impact factor: 3.663

8.  Single-ascending-dose pharmacokinetics and safety of the novel broad-spectrum antifungal triazole BAL4815 after intravenous infusions (50, 100, and 200 milligrams) and oral administrations (100, 200, and 400 milligrams) of its prodrug, BAL8557, in healthy volunteers.

Authors:  Anne Schmitt-Hoffmann; Brigitte Roos; Markus Heep; Michael Schleimer; Erhard Weidekamm; Tom Brown; Michael Roehrle; Christoph Beglinger
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.938

9.  Multiple-dose pharmacokinetics and safety of the new antifungal triazole BAL4815 after intravenous infusion and oral administration of its prodrug, BAL8557, in healthy volunteers.

Authors:  Anne Schmitt-Hoffmann; Brigitte Roos; Jürgen Maares; Markus Heep; Jochen Spickerman; Erhard Weidekamm; Tom Brown; Michael Roehrle
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.938

10.  CDC Recommendations for Hepatitis C Screening Among Adults - United States, 2020.

Authors:  Sarah Schillie; Carolyn Wester; Melissa Osborne; Laura Wesolowski; A Blythe Ryerson
Journal:  MMWR Recomm Rep       Date:  2020-04-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.